Atlanta, GA – Scibility Media – 10/20/2014.
This article discusses two biotechnology companies: AgenusInc(NASDAQ:AGEN) andCytokinetics, Inc.(NASDAQ:CYTK)
AgenusInc(NASDAQ:AGEN) is a Massachusetts-based biopharmaceutical company that develops immune-oncology candidates. The company’s products include checkpoint modulators, adjuvants, and heat shock protein vaccines. On Oct. 10th, Agenus filed a registration statement that covered the offering of up to $150 million of common stock, warrants, debt securities and units, and preferred stock.
Agenus may soon see its value rise due to its role in the fight against Ebola, which has captured the attention of the United States public ever since a Dallas man was afflicted with the disease. In 2011, the company entered a license agreement with Integrated BioTherapeutics Inc. through which its PS-21 Stimulon adjuvant would be used in the development of a vaccine for Ebola. Testing for Ebola vaccines will notably be expedited due to the government’s sense of urgency.
On Oct. 13th, 2014, the South San Francisco-based Cytokinetics, Inc.(NASDAQ:CYTK) announced that it had completed five Phase 1 clinical trials for the evaluation of CK-2127107 in health volunteers. Additionally, the company has also completed some Phase II readiness activities. The result showed that the drug should is safe for human subjects to use and that the drug increased the response of muscular to neuromuscular input. In other words, Cytokinetics’ test has proven to be successful.
CK-2127107 would be used for the treatment of diseases and medical conditions that are associated with muscle weakness. With Phase II trials set to begin and trading prices near record lows, Cytokinetics investors may want to consider holding onto, and adding to, their shares.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to firstname.lastname@example.org and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.